Table 2 Clinicopathological data of the patients.
From: An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma
Total n = 641 | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Patients | n, % | 227 | 100% | 137 | 100% | 201 | 100% | 76 | 100% | |
Age | Mean ± SD, range | 64 ± 16.5 | 18–97 | 59 ± 14.6 | 25–87 | 59 ± 18.1 | 19–88 | 65 ± 15.2 | 22–96 | |
Sex | Male | n, % | 136 | 59.9% | 70 | 51.1% | 117 | 58.2% | 59 | 77.6% |
Female | n, % | 91 | 40.1% | 67 | 48.9% | 84 | 41.8% | 17 | 22.4% | |
Tumor depth | Unknown | n, % | 0 | 0% | 6 | 4.4% | 13 | 6.5% | 0 | 0% |
≥2 mm | n, % | 126 | 55.5% | 79 | 57.7% | 58 | 28.9% | 51 | 67.1% | |
<2 mm | n, % | 101 | 44.5% | 52 | 37.9% | 130 | 64.6% | 25 | 32.9% | |
Clarke levels | Unknown | n, % | 42 | 18.5% | 6 | 4.4% | 19 | 9.5% | NA | NA |
I | n, % | 1 | 0.4% | 0 | 0% | 1 | 0.5 | NA | NA | |
II | n, % | 24 | 10.6% | 17 | 12.4% | 2 | 1% | NA | NA | |
III | n, % | 25 | 11% | 46 | 33.6% | 30 | 14.9% | NA | NA | |
IV | n, % | 113 | 49.8% | 47 | 34.3% | 145 | 72.1% | NA | NA | |
V | n, % | 22 | 9.7% | 21 | 15.3% | 4 | 2% | NA | NA | |
Ulceration | Unknown | n, % | 88 | 38.8% | 8 | 5.8% | 13 | 6.5% | 5 | 6.6% |
Yes | n, % | 65 | 28.6% | 51 | 37.3% | 37 | 18.4% | 41 | 53.9% | |
No | n, % | 74 | 32.6% | 78 | 56.9% | 151 | 75.1% | 30 | 39.5% | |
Stage | Unknown | n, % | 5 | 2.2% | 15 | 11% | NA | NA | 2 | 2.6% |
I | n, % | 85 | 37.5% | 98 | 71.5% | NA | NA | 0 | 0% | |
II | n, % | 93 | 41.0% | 6 | 4.4% | NA | NA | 59 | 77.6% | |
III | n, % | 42 | 18.5% | 15 | 11% | NA | NA | 15 | 19.8% | |
IV | n, % | 2 | 0.8% | 3 | 2.1% | NA | NA | 0 | 0% | |
Location of primary tumor | Unknown | n, % | NA | NA | NA | NA | 13 | 6.5% | 2 | 2.6% |
Trunk | n, % | NA | NA | NA | NA | 102 | 50.7% | 41 | 53.9% | |
Extremity | n, % | NA | NA | NA | NA | 86 | 42.8% | 33 | 43.5% | |
Follow-up (months) | DSOS | Median, IQT | 44 | 49.3 | 59.9 | 97.7 | 79 | 60.4 | 61.5 | 55 |
